Graduate School of Science and Engineering, Kansai University, 3-3-35 Yamate-cho, Suita-shi, Osaka, 564-0836, Japan.
ORDIST, Kansai University, 3-3-35 Yamate-cho, Suita-shi, Osaka, 564-0836, Japan.
Colloids Surf B Biointerfaces. 2021 Jan;197:111423. doi: 10.1016/j.colsurfb.2020.111423. Epub 2020 Oct 18.
Low-environmental-impact emulsion systems for transdermal drug delivery in topical treatment have gained increasing interest. However, low stability and adverse systemic side effects severely decrease their efficiency. This study proposed a stable oil-in-water (O/W) emulsion loaded with bifonazole (BFZ) as a lipophilic drug stabilized by poly(2-isopropoxy-2-oxo-1,3,2-dioxaphospholane)-modified cellulose nanocrystals (CNC-g-PIPP) as vehicles for topical delivery of lipophilic drugs. We fully characterized stability, BFZ-loaded particle-stabilized emulsions (PEs) for morphology, droplet size, and its distribution. In addition, we evaluated the in vitro drug-releasing capacity and in vitro skin permeation of BFZ in a porcine skin animal model using a side-bi-side® diffusion cell. An O/W BFZ-loaded emulsion stabilized with CNC-g-PIPP particles (BFZ-loaded CP-PE) with a small mean droplet size of 2.54 ± 1.39 μm was developed and was stable for > = 15 days without a significant change in droplet size. The BFZ-loading efficiency in PEs was 83.1 %. BFZ was slowly released over an extended period, and the releasing ratio from BFZ-loaded CP-PE was only 17 % after 48 h. The BFZ-loaded CP-PE showed a ∼4.4-fold increase in BFZ permeation and penetration compared to a conventional surfactant-stabilized emulsion and BFZ control solution. Fluorescence-labeling studies showed that BFZ-loaded CP-PE could well penetrate skin layers from the stratum corneum (SC) to the dermis. In addition, histopathology studies of porcine skin treated with the PE formulation showed an intact SC with unaltered adjacent structures and no observed signs of inflammation. Therefore, the proposed CP-PE shows great potential as a transdermal drug carrier for enhancing lipophilic drug permeation.
用于局部治疗的透皮药物传递的低环境影响乳液系统引起了越来越多的关注。然而,低稳定性和不良的全身副作用严重降低了它们的效率。本研究提出了一种稳定的油包水(O/W)乳液,其中含有比伏康唑(BFZ)作为亲脂性药物,由聚(2-异丙氧基-2-氧代-1,3,2-二氧杂磷杂环戊烷)改性纤维素纳米晶体(CNC-g-PIPP)稳定作为亲脂性药物的局部递送载体。我们全面表征了稳定性、载有 BFZ 的颗粒稳定乳液(PE)的形态、粒径及其分布。此外,我们使用侧-侧扩散池在猪皮动物模型中评估了 BFZ 的体外药物释放能力和体外皮肤渗透。开发了一种由 CNC-g-PIPP 颗粒稳定的 O/W BFZ 载药乳液(载 BFZ 的 CP-PE),其平均粒径较小,为 2.54 ± 1.39 μm,且在 > = 15 天内稳定,粒径无明显变化。PE 中的 BFZ 载药量为 83.1%。BFZ 缓慢释放,48 h 后载 BFZ 的 CP-PE 的释放比例仅为 17%。与传统表面活性剂稳定乳液和 BFZ 对照溶液相比,载 BFZ 的 CP-PE 使 BFZ 的渗透和穿透增加了约 4.4 倍。荧光标记研究表明,载 BFZ 的 CP-PE 可以很好地穿透皮肤从角质层(SC)到真皮。此外,用 PE 制剂处理的猪皮的组织病理学研究显示 SC 完整,相邻结构未改变,未观察到炎症迹象。因此,所提出的 CP-PE 显示出作为增强亲脂性药物渗透的透皮药物载体的巨大潜力。
Colloids Surf B Biointerfaces. 2021-1
Int J Pharm. 2009-4-17
J Microencapsul. 2013-3-19
Int J Pharm. 2009-2-23
Colloids Surf B Biointerfaces. 2015-1-9
Molecules. 2024-6-24
Sci Technol Adv Mater. 2021-5-28
Molecules. 2021-5-21